Endocarditis antithrombotic therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Changes made per Mahshid's request) |
||
| (7 intermediate revisions by 4 users not shown) | |||
| Line 4: | Line 4: | ||
{{CMG}}; '''Associate Editors-in-Chief:''' {{CZ}} | {{CMG}}; '''Associate Editors-in-Chief:''' {{CZ}} | ||
== | ==Overview== | ||
In patients with endocarditis, antithrombotic therapy may be administered when needed. The [[prothrombin time]] must be carefully monitored as [[anticoagulant]]s may cause or worsen [[hemorrhage]] in patients with endocarditis. [[Heparin]] administration should be avoided if possible. | |||
* [[Anticoagulant]]s can cause or worsen hemorrhage in patients with [[endocarditis]] but may be carefully administered when needed | ==Antithrombotic Therapy== | ||
* The [[prothrombin time]] should be carefully maintained at an INR of 2.0–3.0 | |||
* Anticoagulation should be reversed immediately in the event of CNS complications and interrupted for 1–2 | *[[Anticoagulant]]s can cause or worsen hemorrhage in patients with [[endocarditis]] but may be carefully administered when needed.<ref name= Baddour>{{cite journal | author = Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A.| title = Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America. | journal = Circulation | volume = 111 | issue = 23 | pages = 3167-84 | year = 2005 | id = PMID 15956145 }}</ref> | ||
* Avoid [[heparin]] administration during active [[endocarditis]] if possible | * The [[prothrombin time]] should be carefully maintained at an INR of 2.0–3.0. | ||
* Anticoagulation should be reversed immediately in the event of CNS complications and interrupted for 1–2 weeks after an acute embolic stroke. | |||
* Avoid [[heparin]] administration during active [[endocarditis]] if possible. | |||
==References== | ==References== | ||
| Line 16: | Line 19: | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Intensive care medicine]] | [[Category:Intensive care medicine]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
Latest revision as of 17:39, 18 September 2017
|
Endocarditis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease |
|
Case Studies |
|
Endocarditis antithrombotic therapy On the Web |
|
Risk calculators and risk factors for Endocarditis antithrombotic therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
In patients with endocarditis, antithrombotic therapy may be administered when needed. The prothrombin time must be carefully monitored as anticoagulants may cause or worsen hemorrhage in patients with endocarditis. Heparin administration should be avoided if possible.
Antithrombotic Therapy
- Anticoagulants can cause or worsen hemorrhage in patients with endocarditis but may be carefully administered when needed.[1]
- The prothrombin time should be carefully maintained at an INR of 2.0–3.0.
- Anticoagulation should be reversed immediately in the event of CNS complications and interrupted for 1–2 weeks after an acute embolic stroke.
- Avoid heparin administration during active endocarditis if possible.
References
- ↑ Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A. (2005). "Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): 3167–84. PMID 15956145.